Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of polypeptide fragments of urine osteopontin (OPN) in lung adenocarcinoma

A polypeptide fragment and osteopontin technology, which is applied in the preparation of test samples, material separation, and material inspection products, can solve the problems of poor patient acceptance, older lung adenocarcinoma patients, and no specific clinical symptoms, etc. To achieve the effect of convenient storage

Active Publication Date: 2018-05-11
张曼
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the early detection of lung adenocarcinoma is hindered by the following factors: first, there are no specific clinical symptoms in the early stage of the disease; Third, low-dose spiral CT has a high false positive rate and is expensive, so it is not suitable for extensive screening
In addition, radiation exposure may increase lung cancer risk
Currently, there are no biomarkers with satisfactory sensitivity and specificity for the diagnosis and treatment of lung adenocarcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polypeptide fragments of urine osteopontin (OPN) in lung adenocarcinoma
  • Application of polypeptide fragments of urine osteopontin (OPN) in lung adenocarcinoma
  • Application of polypeptide fragments of urine osteopontin (OPN) in lung adenocarcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Urine Specimen Collection and Processing

[0020] Randomly cleaned midstream urine samples were collected from 34 patients with lung adenocarcinoma (Beijing Shijitan Hospital Affiliated to Capital Medical University), centrifuged within 2 hours (1500rpm, 5min), and the supernatant was retained. Store in a -80°C refrigerator after aliquoting. The normal control group consisted of 36 cases (Physical Examination Center, Beijing Shijitan Hospital Affiliated to Capital Medical University). For details, please refer to the following table 1:

[0021] Table 1. Clinical data of the 2 groups

[0022]

Embodiment 2

[0023] Example 2 Magnetic Bead Purification and Isolation of Peptides from Urine Specimens

[0024] Take out the urine sample from the -80°C refrigerator, rethaw at 4°C, centrifuge (3000rpm, 10min), and take the supernatant for later use. Equilibrate Weak Cationic Magnetic Beads (MB-WCX) at room temperature and mix the magnetic bead suspension by hand. Add 10ul of MB-WCX and 10ul of magnetic bead binding buffer into the sample tube, pipette the sample gun up and down to mix well to avoid foaming. Add 5 ul of urine supernatant to the sample tube, mix well and let stand on the magnetic stand for 1 minute to separate the magnetic beads from the suspended liquid. Use a sampling gun to remove the suspended clear liquid, and the tip of the gun should avoid contact with the magnetic beads to avoid absorbing the magnetic beads. Add 100ul of magnetic bead washing buffer into the sample tube, mix well, and then place the sample tube on the magnetic stand for 1 minute, the magnetic b...

Embodiment 3

[0025] Example 3 Spot Targeting and Peptide Spectrum Generation of Urine Specimen

[0026] After calibrating the instrument with a standard, mix 1 μl of eluate with 10 μl of matrix (0.3% α-cyano-4-hydroxycinnamic acid, HCCA), and take 1 μl to spot on the Anchorchip (Autoflex MALDI TOF, Bruker-Dalton) target plate and dry at room temperature. The sample is ionized by nitrogen laser irradiation and then subjected to mass spectrometry analysis, collecting data in the range of 1000-10000 Da, and obtaining a mass spectrogram composed of protein peaks with different mass-to-charge ratios. For each MALDI crystallization point, a total of 400 laser irradiations (50 times for each crystallization point at 8 different positions) were irradiated, and the average value represented one sample, so as to obtain the peptide maps of all samples. The mass spectrograms of the normal control group and lung adenocarcinoma group were analyzed by ClinProTools2.1 analysis software, and the differe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of urine osteopontin (OPN) and polypeptide fragments of the urine osteopontin (OPN) in lung adenocarcinoma, and in particular relates to application of the urine osteopontin (OPN) and the polypeptide fragments of the urine osteopontin (OPN) in preparation of a preparation for detecting and auxiliary diagnosis of the lung adenocarcinoma. Researches confirm that compared with a normal control and a lung adenocarcinoma patient group, the urine osteopontin (OPN) is expressed in a low level in urine of a lung adenocarcinoma patient, and can be used for detection and auxiliary diagnosis of the lung adenocarcinoma. The advantages of non-invasive acquisition, large-scale repeated sampling, and convenient preservation of a urine specimen are played, and the urinespecimen is used to detect the urine osteopontin (OPN) and the polypeptide fragments of the urine osteopontin (OPN).

Description

technical field [0001] The invention relates to the new application of urine osteopontin and its polypeptide, in particular to the application of urine osteopontin and its polypeptide fragment in the diagnosis and treatment of lung adenocarcinoma. Background technique [0002] Lung cancer is one of the tumors with the highest morbidity and mortality worldwide. The latest WHO statistics show that 1.59 million patients die of lung cancer every year worldwide. Lung cancer can be divided into small cell lung cancer (SCLC) and non-small lung cancer (NSCLC) according to pathological types, and NSCLC is further divided into squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and sarcomatoid carcinoma. Wait. With the deepening of lung cancer research, NSCLC is divided into squamous cell carcinoma and non-squamous non-small cell lung cancer according to the existence of driving genes, and non-squamous non-small cell lung cancer mainly refers to lung adenocarcinoma. Lung...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N30/02G01N30/06G01N30/72G01N1/34G01N1/38
CPCG01N1/34G01N1/38G01N30/02G01N30/06G01N30/72G01N33/68G01N33/6851G01N2800/7028
Inventor 张曼王珊珊王巍伟雷婷
Owner 张曼